126 related articles for article (PubMed ID: 16101335)
21. Expression of the MN antigen in cervical papanicolaou smears is an early diagnostic biomarker of cervical dysplasia.
Liao SY; Stanbridge EJ
Cancer Epidemiol Biomarkers Prev; 1996 Jul; 5(7):549-57. PubMed ID: 8827360
[TBL] [Abstract][Full Text] [Related]
22. Quality of screening with conventional Pap smear in Austria - a longitudinal evaluation.
Rásky É; Regitnig P; Schenouda M; Burkert N; Freidl W
BMC Public Health; 2013 Oct; 13():998. PubMed ID: 24152300
[TBL] [Abstract][Full Text] [Related]
23. Screening for cervical cancer, results from Thailand.
Wiwanitkit V
Asian Pac J Cancer Prev; 2006; 7(2):329-30. PubMed ID: 16839233
[TBL] [Abstract][Full Text] [Related]
24. [Cervical smears: towards an optimal screening for cervical cancer].
Leroy JL; Boman F
Presse Med; 2003 Feb; 32(4):174-80. PubMed ID: 12610474
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fluid-based, thin-layer processing and conventional Papanicolaou methods for uterine cervical cytology.
Wang TY; Chen HS; Yang YC; Tsou MC
J Formos Med Assoc; 1999 Jul; 98(7):500-5. PubMed ID: 10463000
[TBL] [Abstract][Full Text] [Related]
26. Pap smears with glandular cell abnormalities: Are they detected by rapid prescreening?
Kanber Y; Charbonneau M; Auger M
Cancer Cytopathol; 2015 Dec; 123(12):739-44. PubMed ID: 26348845
[TBL] [Abstract][Full Text] [Related]
27. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
28. Risk of cervical cancer after a negative Pap smear.
Viikki M; Pukkala E; Hakama M
J Med Screen; 1999; 6(2):103-7. PubMed ID: 10444730
[TBL] [Abstract][Full Text] [Related]
29. No increased risk for cervical cancer after a broader definition of a negative Pap smear.
Rebolj M; van Ballegooijen M; van Kemenade F; Looman C; Boer R; Habbema JD
Int J Cancer; 2008 Dec; 123(11):2632-5. PubMed ID: 18767046
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
31. Low proportion of false-negative smears in the Finnish program for cervical cancer screening.
Lönnberg S; Anttila A; Kotaniemi-Talonen L; Kujari H; Melkko J; Granroth G; Vornanen M; Pietiläinen T; Sankila A; Arola J; Luostarinen T; Nieminen P
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):381-7. PubMed ID: 20142239
[TBL] [Abstract][Full Text] [Related]
32. Cervical cancer screening in a rural population of Zimbabwe.
Thistle PJ; Chirenje ZM
Cent Afr J Med; 1997 Sep; 43(9):246-51. PubMed ID: 9509642
[TBL] [Abstract][Full Text] [Related]
33. Review of cervical smears from 76 women with invasive cervical cancer: cytological findings and medicolegal implications.
Coleman DV; Poznansky JJ
Cytopathology; 2006 Jun; 17(3):127-36. PubMed ID: 16719855
[TBL] [Abstract][Full Text] [Related]
34. Effect of the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88) on the incidence of invasive cervical cancer.
Helfand M; O'Connor GT; Zimmer-Gembeck M; Beck JR
Med Care; 1992 Dec; 30(12):1067-82. PubMed ID: 1453813
[TBL] [Abstract][Full Text] [Related]
35. Interlaboratory reproducibility of atypical glandular cells of undetermined significance: a national survey.
Confortini M; Di Bonito L; Carozzi F; Ghiringhello B; Montanari G; Parisio F; Prandi S;
Cytopathology; 2006 Dec; 17(6):353-60. PubMed ID: 17168918
[TBL] [Abstract][Full Text] [Related]
36. Clinical Factors Associated with Specimen Adequacy for Conventional Cervical Cytology in Thammasat University Hospital, Thailand.
Anantaworapot A; Manusook S; Tanprasertkul C; Lertvutivivat S; Chanthasenanont A; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4209-4212. PubMed ID: 27797219
[TBL] [Abstract][Full Text] [Related]
37. High-grade cervical abnormalities and screening intervals in New South Wales, Australia.
Schindeler S; Morrell S; Zuo Y; Baker D
J Med Screen; 2008; 15(1):36-43. PubMed ID: 18416954
[TBL] [Abstract][Full Text] [Related]
38. A quality control system involving peer review of abnormal cervical smears.
Palli D; Confortini M; Biggeri A; Russo A; Cariaggi P; Carozzi F; Minuti PA
Cytopathology; 1993; 4(1):17-25. PubMed ID: 8453014
[TBL] [Abstract][Full Text] [Related]
39. [Cervical-vaginal smears: an unpopular test!].
Gompel C
Presse Med; 1998 Jun; 27(20):971-3. PubMed ID: 9767844
[TBL] [Abstract][Full Text] [Related]
40. Atypical Glandular Cells: Interobserver Variability according to Clinical Management.
Lepe M; Eklund CM; Quddus MR; Paquette C
Acta Cytol; 2018; 62(5-6):397-404. PubMed ID: 29969775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
